{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:33:35Z","timestamp":1781793215688,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T00:00:00Z","timestamp":1420761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00246-014-1089-x","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T10:08:06Z","timestamp":1420711686000},"page":"842-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Utility of a Dedicated Pediatric Cardiac Anticoagulation Program: The Boston Children\u2019s Hospital Experience"],"prefix":"10.1007","volume":"36","author":[{"given":"Jenna M.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Dionne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Mittler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Harney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Manzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"VanderPluym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Almond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,9]]},"reference":[{"issue":"16","key":"1089_CR1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/CIRCULATIONAHA.112.000685","volume":"127","author":"CS Almond","year":"2013","unstructured":"Almond CS, Morales DL, Blackstone EH et al (2013) Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. Circulation 127(16):1702\u20131711","journal-title":"Circulation"},{"key":"1089_CR2","unstructured":"Bauman M. Email to CS Almond regarding Methodology for calculating the Percent Time within Therapeutic Range used in the Edmonton KidClot Program, 30 Dec 2013"},{"issue":"5","key":"1089_CR3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.thromres.2008.07.012","volume":"123","author":"ME Bauman","year":"2009","unstructured":"Bauman ME, Black K, Kuhle S et al (2009) KIDCLOT: the importance of validated educational intervention for optimal long term warfarin management in children. Thromb Res 123(5):707\u2013709","journal-title":"Thromb Res"},{"issue":"22","key":"1089_CR4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","volume":"368","author":"DH Birnie","year":"2013","unstructured":"Birnie DH, Healey JS, Wells GA et al (2013) Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 368(22):2084\u20132093","journal-title":"N Engl J Med"},{"issue":"19","key":"1089_CR5","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/CIRCULATIONAHA.105.577601","volume":"113","author":"ED Blume","year":"2006","unstructured":"Blume ED, Naftel DC, Bastardi HJ et al (2006) Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study. Circulation 113(19):2313\u20132319","journal-title":"Circulation"},{"issue":"15","key":"1089_CR6","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1161\/CIRCULATIONAHA.108.190748","volume":"118","author":"RO Bonow","year":"2008","unstructured":"Bonow RO, Carabello BA, Chatterjee K et al (2008) Focused update incorporated into the ACC\/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118(15):e523\u2013e661","journal-title":"Circulation"},{"issue":"11","key":"1089_CR7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.healun.2013.07.012","volume":"32","author":"AG Cabrera","year":"2013","unstructured":"Cabrera AG, Sundareswaran KS, Samayoa AX et al (2013) Outcomes of pediatric patients supported by the HeartMate II left ventricular assist device in the United States. J Heart Lung Transplant 32(11):1107\u20131113","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"1089_CR8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"5","key":"1089_CR9","doi-asserted-by":"crossref","first-page":"e000136","DOI":"10.1161\/JAHA.113.000136","volume":"2","author":"CL Cove","year":"2013","unstructured":"Cove CL, Hylek EM (2013) An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc 2(5):e000136","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"1089_CR10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/archinte.164.12.1319","volume":"164","author":"JD Douketis","year":"2004","unstructured":"Douketis JD, Johnson JA, Turpie AG (2004) Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 164(12):1319\u20131326","journal-title":"Arch Intern Med"},{"issue":"2 Suppl","key":"1089_CR11","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","volume":"141","author":"JD Douketis","year":"2012","unstructured":"Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e326S\u2013e350S","journal-title":"Chest"},{"issue":"Suppl A100","key":"1089_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1747-4949.2012.00925.x","volume":"8","author":"MM Dowling","year":"2013","unstructured":"Dowling MM, Hynan LS, Lo W et al (2013) International paediatric stroke study: stroke associated with cardiac disorders. Int J Stroke 8(Suppl A100):39\u201344","journal-title":"Int J Stroke"},{"issue":"22","key":"1089_CR13","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.2174\/1381612811319220010","volume":"19","author":"P Eijgenraam","year":"2013","unstructured":"Eijgenraam P, Ten Cate H, Ten Cate-Hoek A (2013) Safety and efficacy of bridging with low molecular weight heparins: a systematic review and partial meta-analysis. Curr Pharm Des 19(22):4014\u20134023","journal-title":"Curr Pharm Des"},{"issue":"2","key":"1089_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.amjcard.2003.09.054","volume":"93","author":"J Fanikos","year":"2004","unstructured":"Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ (2004) Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 93(2):247\u2013250","journal-title":"Am J Cardiol"},{"issue":"6","key":"1089_CR15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa1014164","volume":"367","author":"CD Fraser Jr","year":"2012","unstructured":"Fraser CD Jr, Jaquiss RD, Rosenthal DN et al (2012) Prospective trial of a pediatric ventricular assist device. N Engl J Med 367(6):532\u2013541","journal-title":"N Engl J Med"},{"issue":"10","key":"1089_CR16","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.amjcard.2012.06.057","volume":"110","author":"H Ghanbari","year":"2012","unstructured":"Ghanbari H, Phard WS, Al-Ameri H et al (2012) Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol 110(10):1482\u20131488","journal-title":"Am J Cardiol"},{"issue":"4","key":"1089_CR17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/2150135112460866","volume":"3","author":"TM Giglia","year":"2012","unstructured":"Giglia TM, Dinardo J, Ghanayem NS et al (2012) Bleeding and thrombotic emergencies in pediatric cardiac intensive care: unchecked balances. World J Pediatr Congenit Heart Surg 3(4):470\u2013491","journal-title":"World J Pediatr Congenit Heart Surg"},{"issue":"24","key":"1089_CR18","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","volume":"128","author":"TM Giglia","year":"2013","unstructured":"Giglia TM, Massicotte MP, Tweddell JS et al (2013) Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the american heart association. Circulation 128(24):2622\u20132703","journal-title":"Circulation"},{"issue":"3","key":"1089_CR19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ccd.24737","volume":"82","author":"AC Glatz","year":"2013","unstructured":"Glatz AC, Shah SS, McCarthy AL et al (2013) Prevalence of and risk factors for acute occlusive arterial injury following pediatric cardiac catheterization: a large single-center cohort study. Catheter Cardiovasc Interv 82(3):454\u2013462","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"1089_CR20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.105.598268","volume":"113","author":"SZ Goldhaber","year":"2006","unstructured":"Goldhaber SZ (2006) \u201cBridging\u201d and mechanical heart valves: perils, promises, and predictions. Circulation 113(4):470\u2013472","journal-title":"Circulation"},{"issue":"11","key":"1089_CR21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992","journal-title":"N Engl J Med"},{"issue":"3","key":"1089_CR22","first-page":"285","volume":"16","author":"C Hammerstingl","year":"2007","unstructured":"Hammerstingl C, Tripp C, Schmidt H, von der Recke G, Omran H (2007) Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 16(3):285\u2013292","journal-title":"J Heart Valve Dis"},{"key":"1089_CR23","unstructured":"Hemostasis and Thrombosis Center. Nationawide Children\u2019s Hospital. http:\/\/www.nationwidechildrens.org\/hemostasis-and-thrombosis-center . Accessed Feb 24 2014"},{"issue":"8","key":"1089_CR24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","volume":"360","author":"TE Klein","year":"2009","unstructured":"International Warfarin Pharmacogenetics C, Klein TE, Altman RB et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753\u2013764","journal-title":"N Engl J Med"},{"issue":"1","key":"1089_CR25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.107.738559","volume":"117","author":"P Khairy","year":"2008","unstructured":"Khairy P, Fernandes SM, Mayer JE Jr et al (2008) Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117(1):85\u201392","journal-title":"Circulation"},{"issue":"24","key":"1089_CR26","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","volume":"369","author":"SE Kimmel","year":"2013","unstructured":"Kimmel SE, French B, Kasner SE et al (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369(24):2283\u20132293","journal-title":"N Engl J Med"},{"issue":"3","key":"1089_CR27","first-page":"209","volume":"18","author":"M Lala","year":"2013","unstructured":"Lala M, Burckart GJ, Takao CM, Pravica V, Momper JD, Gobburu JV (2013) Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging. J Pediatr Pharmacol Ther: JPPT 18(3):209\u2013219","journal-title":"J Pediatr Pharmacol Ther: JPPT"},{"key":"1089_CR28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.113.008428","volume":"130","author":"BW McCrindle","year":"2014","unstructured":"McCrindle BW, Li JS, Manlhiot C et al (2014) Challenges and priorities for research: a report from the NHLBI\/NIH Working Group on Thrombosis in Pediatric Cardiology and Congenital Heart Disease. Circulation 130:1192\u20131203","journal-title":"Circulation"},{"issue":"4","key":"1089_CR29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/CIRCULATIONAHA.105.575571","volume":"113","author":"P Meurin","year":"2006","unstructured":"Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A (2006) Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 113(4):564\u2013569","journal-title":"Circulation"},{"issue":"2 Suppl","key":"1089_CR30","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","volume":"141","author":"P Monagle","year":"2012","unstructured":"Monagle P, Chan AK, Goldenberg NA et al (2012) Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e737S\u2013e801S","journal-title":"Chest"},{"key":"1089_CR31","unstructured":"National patient safety goal (03.05.01) for anticoagulation. http:\/\/www.jointcommission.org\/assets\/1\/6\/HAP_NPSG_Chapter_2014.pdf . Accessed Feb 24 2014"},{"issue":"10","key":"1089_CR32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"key":"1089_CR33","unstructured":"Percent time in therapeutic INR range (TTR): mean TTR achieved among patients who received prescriptions for warfarin and had sufficient INR values to calculate TTR. National Quality Measures Clearinghouse (NQMC). Agency for Healthcare Research and Quality (AHRQ). http:\/\/www.qualitymeasures.ahrq.gov\/content.aspx?id=32739 . Accessed Feb 24 2014"},{"issue":"24","key":"1089_CR34","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","volume":"369","author":"M Pirmohamed","year":"2013","unstructured":"Pirmohamed M, Burnside G, Eriksson N et al (2013) A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369(24):2294\u20132303","journal-title":"N Engl J Med"},{"issue":"1","key":"1089_CR35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/CIRCOUTCOMES.110.957738","volume":"4","author":"AJ Rose","year":"2011","unstructured":"Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR (2011) Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the veterans affairs study to improve anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 4(1):22\u201329","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"1089_CR36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236\u2013239","journal-title":"Thromb Haemost"},{"issue":"6","key":"1089_CR37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2710.2008.00959.x","volume":"33","author":"F Ryan","year":"2008","unstructured":"Ryan F, Byrne S, O\u2019Shea S (2008) Managing oral anticoagulation therapy: improving clinical outcomes. A review. J Clin Pharm Ther 33(6):581\u2013590","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1089_CR38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.healun.2012.11.006","volume":"32","author":"ML Stein","year":"2013","unstructured":"Stein ML, Bruno JL, Konopacki KL, Kesler S, Reinhartz O, Rosenthal D (2013) Cognitive outcomes in pediatric heart transplant recipients bridged to transplantation with ventricular assist devices. J Heart Lung Transplant 32(2):212\u2013220","journal-title":"J Heart Lung Transplant"},{"key":"1089_CR39","unstructured":"Thrombosis and Anticoagulation Program; Boston Children\u2019s Hospital. http:\/\/www.childrenshospital.org\/centers-and-services\/programs\/o-_-z\/thrombosis-and-anticoagulation-program\/overview . Accessed Feb 14 2014"},{"key":"1089_CR40","unstructured":"Thrombosis Clinical Program. Texas Children\u2019s Hospital. http:\/\/txch.org\/hematology-center\/hemophilia-thrombosis-center\/thrombosis-clinic\/ . Accessed Feb 24 2014"},{"key":"1089_CR41","unstructured":"Thrombosis Program. The Children\u2019s Hospital of Philadelphia. http:\/\/www.chop.edu\/service\/hematology\/our-programs\/hemostasis-and-thrombosis-center\/thrombosis-program.html . Accessed Feb 24 2014"},{"issue":"19","key":"1089_CR42","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","volume":"33","author":"A Vahanian","year":"2012","unstructured":"Vahanian A, Alfieri O, Andreotti F et al (2012) Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33(19):2451\u20132496","journal-title":"Eur Heart J"},{"issue":"2","key":"1089_CR43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","volume":"1","author":"Y Wan","year":"2008","unstructured":"Wan Y, Heneghan C, Perera R et al (2008) Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1(2):84\u201391","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1089_CR44","unstructured":"(2013) Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire Int 22(139):155\u2013159"},{"issue":"7","key":"1089_CR45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","volume":"34","author":"DM Siegal","year":"2013","unstructured":"Siegal DM, Crowther MA (2013) Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 34(7):489\u2013498b","journal-title":"Eur Heart J"},{"issue":"6","key":"1089_CR46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00392-013-0560-7","volume":"102","author":"T Steiner","year":"2013","unstructured":"Steiner T, Bohm M, Dichgans M et al (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 102(6):399\u2013412","journal-title":"Clin Res Cardiol"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-014-1089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00246-014-1089-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-014-1089-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T10:52:11Z","timestamp":1650970331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00246-014-1089-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,9]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s00246-014-1089-x","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,9]]}}}